The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The efficacy & role of iberdomide in R/R multiple myeloma
Al-Ola Abdallah, MD, University of Kansas Medical Center, Westwood, KS, shares insights into the efficacy and role of iberdomide in relapsed/refractory (R/R) multiple myeloma. Dr Abdallah anticipates that future efforts will look at combining iberdomide with other agents to increase response rates (R/R) but notes that direct comparison in randomized trials is required to confirm whether cereblon E3 ligase modulators (CELMoDs) are more effective and less toxic than other immunomodulatory drugs. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
